article thumbnail

Fragile X syndrome market to quadruple to $111.9 million in US and Germany by 2030, forecasts GlobalData

Express Pharma

million by 2030, a CAGR of 31.3 per cent (2025-2030), driven by the anticipated launch of two high-priced targeted therapies for FXS in 2027, according to GlobalData. There are currently no approved therapies available for FXS; prescribed treatment consists exclusively of off-label drugs that target individual symptoms of the disease.

article thumbnail

Race for approval of first oral GLP-1R drug in obesity intensifies with four in phase III trials: GlobalData

Express Pharma

By 2030, half of all US adults are predicted to be obese (New England Journal of Medicine). The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity.

Labelling 126
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030

Express Pharma

billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. billion by 2030. Despite its forecasted sales performance paling in comparison to Pluvicto by 2030, the use of alpha-emitting actinium-225 could prove to be the future of RLTs in this therapeutic landscape.

article thumbnail

FDA expands Novartis’ Kisqali label to include early breast cancer patients

Pharmaceutical Technology

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData analysis.

article thumbnail

Strengthening our presence within APAC through increased penetration is a key focus

Express Pharma

In addition, the nutra market boom in APAC that began during the COVID-19 pandemic continues to accelerate looking for green-label, plant-based capsules for encapsulation. We also see a growing emphasis on sustainable practices in manufacturing and packaging, aligning with global trends in reducing carbon footprint and waste.

Labelling 104
article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

article thumbnail

FDA rejection to delay Lebrikizumab chances to enter atopic dermatitis market: GlobalData

Express Pharma

Despite this setback, the CRL being issued was not because of inadequacies or concerns regarding lebrikizumab’s Phase III efficacy and safety data that supported the BLA to the FDA or concerns with the proposed US label of the product. billion across the 7MM for AD in 2030.

Labelling 105